Skip to content

Compounds · Metabolic & weight · Fat metabolism regulation and weight management

AOD9604 (hGH Fragment 176-191)

Full protocol

AOD-9604, AOD 9604, hGH Fragment 176-191, Tyr-hGH Fragment 177-191

Fragment of human growth hormone (amino acids 176–191) engineered in the 1990s to isolate hGH’s fat-burning action from its growth effects. Studied for fat loss and possibly joint/tissue repair; remains investigational with no approval.

0.3 mg daily, fasted

Research score 60/100. Reference only, not a prescription.

  • Fat Loss
  • Metabolic Enhancement
  • Joint Support
  • Recovery Enhancement
  • Anti-inflammatory
US status
Research Chemical
Approval
Research Chemical Only
Evidence
Investigational for obesity and tissue repair. Clinical evidence is limited compared to approved metabolic drugs. No FDA approval.
Research score
60 / 100
Indication
Research Only - No Medical Indication
Origin
Australia
Source category
Muscles & Joints
Status group
Research chemical

Mechanism

Mimics hGH’s lipid effects via β3-adrenergic receptor activation in fat tissue, raising cAMP/PKA signaling and hormone-sensitive lipase activity to break down triglycerides, without affecting glucose or IGF-1.

Safety file

Generally well tolerated; mild injection-site reactions, headache, nausea reported. Unlike hGH it doesn’t raise IGF-1 or cause insulin resistance, but WADA prohibits it.

  • Injection site reactions
  • Temporary fatigue
  • Headache

Reconstitution

Concentration by vial size and water volume
Vial1 mL total2 mL total
5 mg5 mg/mL2.5 mg/mL

Reconstitutes with bacteriostatic water. If a vial stays cloudy, some dissolve it in a small amount of 0.6% acetic acid first (about 10 to 20% of the target volume), then top up with bac water; the acid counts toward the final volume.

  1. Add 0.6% acetic acid first, about 10 to 20% of your target volume (roughly 0.2 to 0.4 mL for a 2 mL fill), down the inside wall of the vial.
  2. Add bacteriostatic water slowly to reach your target volume (about 1.6 to 1.8 mL for a 2 mL fill), swirling as you go.
  3. Swirl gently until the solution is clear. Do not shake.
  4. If a vial has already gone cloudy in plain bac water, adding 0.6% acetic acid will usually clear it. If it stays cloudy after the acid, the peptide has aggregated and the vial should be discarded.

Full mixing method

Protocol

Route: Subcutaneous

Standard protocol (subcutaneous)

  • 0.3 mg (300 mcg) per day, injected fasted in the morning
  • At a 2 mL fill on the 5 mg vial (2.5 mg/mL), 0.3 mg is a 0.12 mL draw (12 units)

Dosing detail

  • Standard dose is 0.3 mg (300 mcg) daily, usually fasted in the morning.
  • A modified GH fragment that targets fat metabolism without raising IGF-1 or overall GH, so it does not cause the water retention or growth effects of HGH.
  • Daily consistency over a cycle is the approach.
  • Well tolerated in human trials, but those trials did not show meaningful weight loss.

Duration

  • Run several weeks to a few months, daily. Often paired with a GH secretagogue like Ipamorelin (AOD in the morning, Ipamorelin before bed).

Notes

  • A fragment of GH studied for fat metabolism without the broader GH effects.
  • Well tolerated in human trials, but those trials did not show meaningful weight loss.
  • Inject subcutaneously and rotate sites.

Storage and handling

  • Keep the powdered (lyophilized) vial in a cool, dark place. Refrigerate it for longer-term storage before mixing.
  • Once reconstituted and refrigerated at 2–8 °C away from light, use the vial within 28 days.
  • Do not freeze a reconstituted vial, and keep it away from heat and sunlight.
  • If the solution turns cloudy, develops floating particles, or shows any other sign of degradation, stop using that vial.
  • Cloudiness right after mixing usually means the wrong diluent, not a bad vial; reach for 0.6% acetic acid before writing it off. Cloudiness that appears days later in a previously clear vial is degradation, and that vial should be discarded.

Storage rules and when to discard